Full-Time

Associate Director

Indirect Procurement

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Schwalmstadt, Germany + 3 more

More locations: Maidenhead, UK | Liverpool, UK | Munich, Germany

In Person

On-site in UK and Germany; occasional travel to other CSL sites.

Bachelor's, Certification

Category
Operations & Logistics (1)
Required Skills
Risk Management
Data Analysis

Get referred to CSL

See people who can refer or advise you

Requirements
  • Bachelor’s degree in business, Supply Chain, or related discipline
  • Professional certification (e.g., CIPS) preferred
  • Minimum 5+ years’ experience in procurement, sourcing, or category management roles
  • Fluency in English and German
  • Travel requirements: 20% travel expected
Responsibilities
  • Develop and implement category strategies aligned with organizational priorities and objectives.
  • Analyze spend, market trends and supply risks to effectively manage procurement activities to ensure cost efficiency and optimal supplier performance.
  • Provide strategic direction and operational support to Sourcing Managers to execute procurement activities.
  • Define category roadmaps, sourcing pipelines, and performance metrics.
  • Build and maintain strong relationships with suppliers to foster collaboration and drive innovation.
  • Facilitate supplier business performance reviews and ensure alignment with contractual and CSL needs and priorities, and establish supplier performance management (KPIs, scorecards, reviews) to improve performance.
  • Lead supplier risk management and continuity planning.
  • Lead Cross Functional Category Councils to ensure CSL and the supply base are aligned both in the immediate term but also across a 5-year pipeline.
  • Engage with internal stakeholders across CSL to align procurement initiatives and saving opportunities.
  • Ensure compliance with procurement policies and governance frameworks and ethical sourcing standards.
  • Maintain accurate documentation and reporting of procurement activities and supplier engagements.
  • Identify and manage procurement-related risks within assigned categories.
  • Lead the Tendering process, negotiations, and contract awards for activities over US$500K.
  • Drive total cost of ownership (TCO) improvements, cost reduction, and value creation.
  • Monitor category performance using key performance indicators (KPIs) and provide insights to the Category Director and key stakeholders across Legal, HR and Finance.
  • Conduct detailed cost analysis and benchmarking to identify savings opportunities and ensure procurement activities align with financial objectives.
  • Monitor and report category performance against budget using KPIs and data-driven insights to support cost optimization and compliance.
  • Partner with internal stakeholders (Enabling Functions, Finance, Legal, etc.) to translate business requirements into sourcing and contracting strategies.
  • Act as the primary procurement point of contact for assigned categories.
  • Risk management.
  • Training and development.
  • Market intelligence sharing.
  • Support change initiatives.
  • Stakeholder engagement.
Desired Qualifications
  • Professional certification such as Chartered Institute of Procurement and Supply (CIPS) preferred
  • Experience in multi-site organizations

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL realized US$176 million FY26 cost savings, above target, improving margins.
  • September 10, 2026 Lancet data strengthens AUJEMFLU's case with older adults and regulators.
  • CSL's VarmX collaboration funds Phase 3 VMX-C001, expanding into urgent-surgery anticoagulation reversal.

What critics are saying

  • FY26 reported a US$2.6 billion loss after US$7.1 billion impairments and restructuring.
  • Pentagon's April 2026 flu mandate repeal cuts Seqirus demand from a major buyer.
  • CSL reported March 2026 temporary global HEMGENIX availability issues, risking treatment continuity and trust.

What makes CSL unique

  • CSL's FY26 portfolio spans plasma, gene therapy, and leading influenza vaccines.
  • HEMGENIX posted 25% FY26 growth, sustaining durable haemophilia B demand.
  • AUJEMFLU won MHRA and European Commission approval, plus Lancet superiority data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.